NEW YORK – Lucid Diagnostics said Tuesday that it has signed a memorandum of understanding with Front Line Mobile Health to explore comarketing and collaboration opportunities to promote Lucid's EsoGuard assay for early detection of esophageal precancer, particularly among firefighters.
Lucid previously collaborated with Front Line, a comprehensive medical care provider for first responders, to facilitate a direct testing event.
Shaun O'Neil, the company's president and chief operating officer, said in a statement that the extended partnership will allow it to expand these efforts through high-volume testing events that it expects to drive revenue.
Financial terms of the new agreement were not disclosed.
EsoGuard is a sequencing-based DNA methylation assay performed on surface esophageal cells that quantifies 31 methylation sites on two genes, vimentin and cyclin A1.